Pilot study of the impact of letrozole vs. placebo on breast density in women completing 5 years of tamoxifen

Breast

Volumn 16, Issue 2, 2007, Pages 204-210

  Vachon, C M ^a   Ingle, J N ^a   Suman, V J ^a   Scott, C G ^a   Gottardt, H ^b   Olson, J E ^a   Goss, P E ^c  

^a Mayo Clinic   (United States)

^b DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^c MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

Aromatase inhibitors; Breast density; Mammographic density

Indexed keywords

AROMATASE INHIBITOR; LETROZOLE; PLACEBO; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; EARLY CANCER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MAMMOGRAPHY; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 33947689213     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2006.10.007     Document Type: Article

References (39)

1. Goss P.E., Ingle J.N., Martino S., Robert N.J., Muss H.B., Piccart M.J., et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA. 17. J Natl Cancer Inst 97 17 (2005) 1262-1271
2. Coombes R.C., Hall E., Gibson L.J., Paridaens R., Jassem J., Delozier T., et al., A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350 11 (2004) 1081-1092
3. Boyd N.F., Rommens J.M., Vogt K., Lee V., Hopper J.L., Yaffe M.J., et al. Mammographic breast density as an intermediate phenotype for breast cancer. Lancet Oncol 6 10 (2005) 798-808
4. Byrne C., Schairer C., Wolfe J., Parekh N., Salane M., Brinton L.A., et al. Mammographic features and breast cancer risk: effects with time, age, and menopause status. J Natl Cancer Inst 87 21 (1995) 1622-1629
5. Boyd N.F., Byng J.W., Jong R.A., Fishell E.K., Little L.E., Miller A.B., et al. Quantitative classification of mammographic densities and breast cancer risk: results from the Canadian National Breast Screening Study. J Natl Cancer Inst 87 9 (1995) 670-675
6. Ursin G., Ma H., Wu A.H., Bernstein L., Salane M., Parisky Y.R., et al. Mammographic density and breast cancer in three ethnic groups. Cancer Epidemiol Biomarkers Prev 12 4 (2003) 332-338
7. Habel L.A., Dignam J.J., Land S.R., Salane M., Capra A.M., and Julian T.B. Mammographic density and breast cancer after ductal carcinoma in situ. J Natl Cancer Inst 96 19 (2004) 1467-1472
8. Greendale G.A., Reboussin B.A., Sie A., Singh H.R., Olson L.K., Gatewood O., et al. Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Postmenopausal Estrogen/Progestin Interventions (PEPI) Investigators. Ann Intern Med 130 4 Pt 1 (1999) 262-269
9. Cyrlak D., and Wong C.H. Mammographic changes in postmenopausal women undergoing hormonal replacement therapy. AJR Am J Roentgenol 161 6 (1993) 1177-1183
10. Laya M.B., Gallagher J.C., Schreiman J.S., Larson E.B., Watson P., and Weinstein L. Effect of postmenopausal hormonal replacement therapy on mammographic density and parenchymal pattern. Radiology 196 2 (1995) 433-437
11. Stomper P.C., Van Voorhis B.J., Ravnikar V.A., and Meyer J.E. Mammographic changes associated with postmenopausal hormone replacement therapy: a longitudinal study. Radiology 174 2 (1990) 487-490
12. Rutter C.M., Mandelson M.T., Laya M.B., Seger D.J., and Taplin S. Changes in breast density associated with initiation, discontinuation, and continuing use of hormone replacement therapy. JAMA 285 2 (2001) 171-176
13. Atkinson C., Warren R., Bingham S.A., and Day N.E. Mammographic patterns as a predictive biomarker of breast cancer risk: effect of tamoxifen. Cancer Epidemiol Biomarkers Prev 8 10 (1999) 863-866
14. Ursin G., Pike M.C., Spicer D.V., Porrath S.A., and Reitherman R.W. Can mammographic densities predict effects of tamoxifen on the breast?. J Natl Cancer Inst 88 2 (1996) 128-129
15. Cuzick J., Warwick J., Pinney E., Warren R.M., and Duffy S.W. Tamoxifen and breast density in women at increased risk of breast cancer. J Natl Cancer Inst 96 8 (2004) 621-628
16. Son H.J., and Oh K.K. Significance of follow-up mammography in estimating the effect of tamoxifen in breast cancer patients who have undergone surgery. AJR Am J Roentgenol 173 4 (1999) 905-909
17. Konez O., Goyal M., and Reaven R.E. Can tamoxifen cause a significant mammographic density change in breast parenchyma?. Clin Imaging 25 5 (2001) 303-308
18. Chow C.K., Venzon D., Jones E.C., Premkumar A., O'Shaughnessy J., and Zujewski J. Effect of tamoxifen on mammographic density. Cancer Epidemiol Biomarkers Prev 9 9 (2000) 917-921
19. Brisson J., Brisson B., Cote G., Maunsell E., Berube S., and Robert J. Tamoxifen and mammographic breast densities. Cancer Epidemiol Biomarkers Prev 9 9 (2000) 911-915
20. Spicer D.V., Ursin G., Parisky Y.R., Pearce J.G., Shoupe D., Pike A., et al. Changes in mammographic densities induced by a hormonal contraceptive designed to reduce breast cancer risk. J Natl Cancer Inst 86 6 (1994) 431-436
21. Gram I.T., Ursin G., Spicer D.V., and Pike M.C. Reversal of gonadotropin-releasing hormone agonist induced reductions in mammographic densities on stopping treatment. Cancer Epidemiol Biomarkers Prev 10 11 (2001) 1117-1120
22. Ingle JN, Tu D, Pater JL, Martino S, Robert NJ, Muss HB, et al. Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial. Breast Cancer Res Treat 2006, in press.
23. Ingle J.N. Endocrine therapy trials of aromatase inhibitors for breast cancer in the adjuvant and prevention settings. Clin Cancer Res 11 2 Pt 2 (2005) 900s-905s
24. Geisler J., Haynes B., Anker G., Dowsett M., and Lonning P.E. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol 20 3 (2002) 751-757
25. Dowsett M., Jones A., Johnston S.R., Jacobs S., Trunet P., and Smith I.E. In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer. Clin Cancer Res 1 12 (1995) 1511-1515
26. Miller W.R., and Dixon J.M. Local endocrine effects of aromatase inhibitors within the breast. J Steroid Biochem Mol Biol 79 1-5 (2001) 93-102
27. Boyd N.F., Stone J., Martin L.J., Jong R., Fishell E., Yaffe M., et al. The association of breast mitogens with mammographic densities. Br J Cancer 87 8 (2002) 876-882
28. Tamimi R.M., Hankinson S.E., Colditz G.A., and Byrne C. Endogenous sex hormone levels and mammographic density among postmenopausal women. Cancer Epidemiol Biomarkers Prev 14 11 Pt 1 (2005) 2641-2647
29. Greendale G.A., Palla S.L., Ursin G., Laughlin G.A., Crandall C., Pike M.C., et al. The association of endogenous sex steroids and sex steroid binding proteins with mammographic density: results from the Postmenopausal Estrogen/Progestin Interventions Mammographic Density Study. Am J Epidemiol 162 9 (2005) 826-834
30. Venta L.A., Hendrick R.E., Adler Y.T., DeLeon P., Mengoni P.M., Scharl A.M., et al. Rates and causes of disagreement in interpretation of full-field digital mammography and film-screen mammography in a diagnostic setting. AJR Am J Roentgenol 176 5 (2001) 1241-1248
31. Stone J., Gunasekara A., Martin L.J., Yaffe M., Minkin S., and Boyd N.F. The detection of change in mammographic density. Cancer Epidemiol Biomarkers Prev 12 7 (2003) 625-630
32. Boyd N.F., Lockwood G.A., Martin L.J., Knight J.A., Jong R.A., Fishell E., et al. Mammographic densities and risk of breast cancer among subjects with a family history of this disease. J Natl Cancer Inst 91 16 (1999) 1404-1408
33. Byng J.W., Boyd N.F., Fishell E., Jong R.A., and Yaffe M.J. The quantitative analysis of mammographic densities. Phys Med Biol 39 10 (1994) 1629-1638
34. Ursin G. Mammographic density as indicator of breast cancer risk. Tidsskr Nor Laegeforen 123 23 (2003) 3373-3376
35. Maskarinec G., Lurie G., Williams A.E., and Le Marchand L. An investigation of mammographic density and gene variants in healthy women. Int J Cancer 112 4 (2004) 683-688
36. Geisler J. Breast cancer tissue estrogens and their manipulation with aromatase inhibitors and inactivators. J Steroid Biochem Mol Biol 86 3-5 (2003) 245-253
37. Haiman C.A., Hankinson S.E., De Vivo I., Guillemette C., Ishibe N., Hunter D.J., et al. Polymorphisms in steroid hormone pathway genes and mammographic density. Breast Cancer Res Treat 77 1 (2003) 27-36
38. Dunning A.M., Dowsett M., Healey C.S., Tee L., Luben R.N., Folkerd E., et al. Polymorphisms associated with circulating sex hormone levels in postmenopausal women. J Natl Cancer Inst 96 12 (2004) 936-945
39. Ma C.X., Adjei A.A., Salavaggione O.E., Coronel J., Pelleymounter L., Wang L., et al. Human aromatase: gene resequencing and functional genomics. Cancer Res 65 23 (2005) 11071-11082